FIORENTINI, Chiara
 Distribuzione geografica
Continente #
NA - Nord America 4.170
EU - Europa 2.195
AS - Asia 1.187
SA - Sud America 8
Continente sconosciuto - Info sul continente non disponibili 6
AF - Africa 4
OC - Oceania 4
Totale 7.574
Nazione #
US - Stati Uniti d'America 4.152
CN - Cina 604
UA - Ucraina 510
IT - Italia 447
PL - Polonia 378
DE - Germania 242
SG - Singapore 236
FI - Finlandia 183
FR - Francia 134
HK - Hong Kong 132
IE - Irlanda 97
GB - Regno Unito 95
TR - Turchia 86
IN - India 71
BE - Belgio 31
SE - Svezia 24
VN - Vietnam 20
CZ - Repubblica Ceca 18
CA - Canada 15
IR - Iran 15
ID - Indonesia 10
NL - Olanda 10
LU - Lussemburgo 7
EU - Europa 6
AU - Australia 4
CL - Cile 3
ES - Italia 3
KG - Kirghizistan 3
BG - Bulgaria 2
BR - Brasile 2
EG - Egitto 2
JP - Giappone 2
LV - Lettonia 2
MX - Messico 2
PE - Perù 2
PT - Portogallo 2
RO - Romania 2
RU - Federazione Russa 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
AR - Argentina 1
AT - Austria 1
CH - Svizzera 1
GE - Georgia 1
HU - Ungheria 1
IL - Israele 1
JO - Giordania 1
KR - Corea 1
LT - Lituania 1
MA - Marocco 1
PA - Panama 1
PK - Pakistan 1
SI - Slovenia 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 7.574
Città #
Fairfield 556
Woodbridge 487
Jacksonville 390
Warsaw 378
Houston 323
Ashburn 275
Chandler 274
Cambridge 212
Brescia 207
Seattle 202
Singapore 199
Ann Arbor 196
Wilmington 184
Princeton 182
Nanjing 134
Hong Kong 130
New York 122
Helsinki 108
Dublin 97
Beijing 89
Istanbul 75
Dearborn 70
Nanchang 48
Shanghai 42
Hebei 39
Shenyang 38
Des Moines 34
Milan 34
San Diego 32
Tianjin 32
Jinan 30
Brussels 27
Changsha 27
Pune 26
Lancaster 23
Jiaxing 22
San Mateo 22
Dong Ket 20
San Donà Di Piave 17
Hangzhou 16
Kunming 16
Munich 15
Brno 14
London 14
San Francisco 14
Ardabil 13
Leawood 13
Toronto 12
Los Angeles 11
Verona 11
Jakarta 10
Ningbo 10
Kocaeli 9
Augusta 8
Fuzhou 8
Monmouth Junction 8
Boardman 7
Dudelange 7
Guangzhou 7
Isola Vicentina 7
Lappeenranta 7
Norwalk 7
Taizhou 6
Zhengzhou 6
Teramo 5
Acton 4
Brooklyn 4
Changchun 4
Haikou 4
Kilburn 4
Leipzig 4
Phoenix 4
Redmond 4
Salerno 4
West Jordan 4
Auburn Hills 3
Bishkek 3
Bolzano 3
Chicago 3
Cinisello Balsamo 3
Espoo 3
Hefei 3
Macerata 3
Mons 3
Olomouc 3
Portland 3
Santa Clara 3
Turin 3
Vicenza 3
Amsterdam 2
Berlin 2
Cairo 2
Canberra 2
Central 2
Genova 2
Groningen 2
Gunzenhausen 2
Hanover 2
Lanzhou 2
Lima 2
Totale 5.768
Nome #
MURC/cavin-4 is co-expressed with Caveolin-3 in rhabdomyosarcoma tumors and its silencing prevents myogenic differentiation in the human embryonal RD cell line 280
GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity 237
Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study. 189
Immunotherapy failure in adrenocortical cancer: where next? 164
Social networks and health status in the elderly: the ‘ANZIANI IN-RETE’ population-based study 163
The "in situ" proximity ligation assay to probe protein-protein interactions in intact tissues 161
Role of Dopamine D2/D3 Receptors in Development, Plasticity, and Neuroprotection in Human iPSC-Derived Midbrain Dopaminergic Neurons 158
IN VITRO ANTITUMOR ACTIVITY OF PROGESTERONE IN HUMAN ADRENOCORTICAL CARCINOMA 149
MURC/cavin-4 is co-expressed with Caveolin-3 in rhabdomyosarcoma tumors and its silencing prevents myogenic differentiation in the human embryonal RD cell line 147
Palbociclib inhibits proliferation of human adrenocortical tumor cells 136
The D3 dopamine receptor: From structural interactions to function. 135
Kainate Receptor RNA Editing is Markedly Altered by Acute Spinal Cord Injury. 127
Persistent activation of the D1R/Shp-2/Erk1/2 pathway in L-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease 126
Shp-2 knockdown prevents l-dopa-induced dyskinesia in a rat model of Parkinson's disease 126
Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma. 124
Dopamine D3 and acetylcholine nicotinic receptor heteromerization in midbrain dopamine neurons: Relevance for neuroplasticity 121
The novel hybrid agonist HyNDA-1 targets the D3R-nAChR heteromeric complex in dopaminergic neurons 118
The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease 116
Bifunctional compounds targeting both D2 and non-α7 nACh receptors: design, synthesis and pharmacological characterization. 115
Exploring pre-degenerative alterations in humans using induced pluripotent stem cell-derived dopaminergic neurons 111
Receptor Heteromers in Parkinson's Disease and L-DOPA-Induced Dyskinesia 110
Ormoni Anteroipofisari 109
The tyrosine phosphatase Shp-2 interacts with the dopamine D(1) receptor and triggers D(1) -mediated Erk signaling in striatal neurons. 109
Nicotine prevents alpha-synuclein accumulation in mouse and human iPSC-derived dopaminergic neurons through activation of the dopamine D3- acetylcholine nicotinic receptor heteromer 107
The neurobiology of dopamine receptors: evolution from the dual concept to heterodimer complexes 106
Chronic glutamate treatment selectively modulates AMPA RNA editing and ADAR expression and activity in primary cortical neurons 106
The NMDA/D1 receptor complex as a new target in drug development 100
Dimerization of dopamine D1 and D3 receptors in the regulation of striatal function 100
Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease. 99
Nerve growth factor suppresses the tumoral phenotype of human prolactinomas 98
CaMKII-dependent phosphorylation regulates SAP97/NR2A interaction 93
Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization 91
Nerve growth factor regulates dopamine D2 receptor expression in prolactinoma cell lines via p75NGFR-mediated activation of nuclear factor-kB. 89
Group-II metabotropic glutamate receptors negatively modulate NMDA transmission at striatal cholinergic terminals: Role of P/Q-type high voltage activated Ca++ channels and endogenous dopamine 88
Nerve growth factor and retinoic acid interactions in the control of small cell lung cancer proliferation. 86
D1 receptor properties are modulated by its oligomerization with NMDA receptors 81
Dopamine D3 receptors are critically involved in the neurotrophic effects of cocaine and nicotine on the mouse mesencephalic dopaminergic neurons 78
Dopamine D3 receptor heteromerization: Implications for neuroplasticity and neuroprotection 78
D1 and D3 dopamine receptors form heterooligomers and cointernalization after paired activation of both receptors 77
Modulation by chronic stress and ketamine of ionotropic AMPA/NMDA and metabotropic glutamate receptors in the rat hippocampus 77
Generation of two human induced pluripotent stem cell lines, UNIBSi012-A and UNIBSi013-A, from two patients with treatment-resistant depression 77
Molecular and pharmacological detection of dopaminergic receptors in the human male urinary tract 76
Dopamine-induced Erk activation in striatal neurons is mediated by a direct interaction between the D1 receptor and the tyrosine phosphatase Shp-2. 76
Eterodimerizzazione tra recettori dopaminergici D1 e D3: implicazioni funzionali e farmacologiche 74
Downregulation of dopamine D1/ glutamate NMDA receptor complexes in L-DOPA-induced dyskinesia in the rat 73
Role of dopamine D3R/nAChR heterodimeric complex in the regulation of dopaminergic neurons function. 73
D1 receptor signalling in basal ganglia function and dysfunctions. 73
Phenotype changes of prolactinomas 72
A direct interaction between dopamine D1 receptor and phosphatase Shp-2 triggers Erk activation in striatal neurons 72
The Shp-2 tyrosine phosphatase interacts with the dopamine D1 receptor and triggers D1-mediated Erk signalling in striatal neurons. 71
Neurotrophic effects of cocaine on mouse mesencephalic dopaminergic neurons are mediated by dopamine D3 receptors 71
Dopamine D1R activation modulates intracellular signalling and triggers Erk1/2 activation in striatal neurons through the interaction with the protein tyrosine phosphatase Shp-2. 70
Dopamine D1R activation triggers Erk1/2 activation in striatal neurons through the interaction with the protein tyrosine phosphatase Shp-2. 70
Down-regulation of the D1R/Shp-2/Erk1/2 pathway ameliorates L-DOPA-induced dyskinesia in the 6-Hydroxy-Dopamine rat model of Parkinson's disease. 68
Dopamine agonists produce neurotrophic effects on mesencephalic dopaminergic neurons via dopamine D3 receptor activation 66
In-vivo silencing of the tyrosine phosphatase Shp-2 ameliorates L-DOPA-induced dyskinesia in a rat model of Parkinson’s disease 65
Establishment and characterization of induced pluripotent stem cell (iPSCs) line UNIBSi014-A from a healthy female donor 63
Role of dopamine D3R and acetylcholine nicotinic receptor interaction in the regulation of dopaminergic neurons function. 60
Impaired dopamine D3 and nicotinic acetylcholine receptor membrane localization in iPSCs-derived dopaminergic neurons from two Parkinson's disease patients carrying the LRRK2 G2019S mutation 60
Role of D1 and D3 dopamine receptor heterodimerization in the regulation of the receptor signalling 59
Oligomeric assembly of dopamine D1 and glutamate NMDA receptors: molecular mechanisms and functional implications 57
Molecular mechanisms underlying dopamine D1R-dependent activation of striatal Erk1/2 in L-DOPA induced dyskinesia in a rat model of Parkinson’s disease. 57
Ormoni anteroipofisari 57
Oligomerization and trafficking of the human dopamine transporter: mutational analysis identifies critical domains important for the functional expression of the transporter. 56
Functional implications of dopamine D1 and D3 receptor heterodimerization 56
Receptor dimerization and the regulation of neuronal function 55
Interactions of Dopamine D1 receptors with D3 receptors and glutamate NMDA receptors 55
Regulation of G-protein coupled receptor trafficking by receptor-receptor interaction 55
Role of dopamine D1 receptor and phosphatase Shp-2 in L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. 55
Knock-down of the tyrosine phosphatase Shp-2 ameliorates L-DOPA-induced dyskinesia in a rat model of parkinson's disease. 55
Identification and characterization of two Nf-kB binding sites in the human dopamine d2 receptor promotor 54
Growth factors in pituitary tumors 53
Regulation of dopamine D1 receptor trafficking and desensitization by oligomerization with glutamate NMDA receptors 53
Oligomerization with NMDA receptor as a novel regulatory mechanism of D1 receptor function 52
Regulation of D1 receptor signalling by direct interaction with the protein tyrosine phosphatase SHP-2 51
Ribociclib Cytotoxicity Alone Or Combined With Progesterone And/Or Mitotane In In Vitro Adrenocortical Carcinoma Cells 51
Extracellular clusterin limits the uptake of α-synuclein fibrils by murine and human astrocytes 50
Loss of Synaptic D1 Dopamine/N-Methyl-D-aspartate Glutamate Receptor Complexes in L-DOPA-Induced Dyskinesia in the Rat. 49
Downregulation of dopamine D1/NMDA receptor complexes in the post synaptic densities of dyskinetic rats 49
Role of D1 and D3 dopamine receptor heterodimerization in the regulation of receptor trafficking and function 47
Identification and characterization of two nuclear factor-kappaB sites in the regulatory region of the dopamine D2 receptor. 45
Dendritic remodeling of hippocampal pyramidal neurons, induced by chronic stress and fast-acting antidepressant ketamine, involves miR-9-5p 45
Oligomerization of dopamine D1 and glutamate NMDA receptors: a new mechanism regulating striatal function” 43
Induced pluripotent stem cells for defining Parkinsonian patient subtypes: a further step toward precision medicine 43
Meccanismo molecolari e cellulari nel Morbo di Parkinson 42
miR-9-5p is involved in the rescue of stress-dependent dendritic shortening of hippocampal pyramidal neurons induced by acute antidepressant treatment with ketamine 42
Farmacologia degli ormoni anteroipofisari 39
Frailty and cognitive impairment in elderly patients: miRNAs as new biomarkers (MATCH-In project) 38
MicroRNAs in frailty associated cognitive impairment MATCH In. 32
Structural Plasticity of Dopaminergic Neurons Requires the Activation of the D3R-nAChR Heteromer and the PI3K-ERK1/2/Akt-Induced Expression of c-Fos and p70S6K Signaling Pathway 32
microRNAs as possible biomarkers of frailty and cognitive impairment: the MATCH-In project 30
The Potential Role of miRNAs in Cognitive Frailty 27
Central nervous system interaction and crosstalk between nAChRs and other ionotropic and metabotropic neurotransmitter receptors 25
microRNAs as new biomarkers in frailty associated with cognitive impairment in elderly patients (MATCH-In project) 25
Recent Advances in Dopamine D3 Receptor Heterodimers: Focus on Dopamine D3 and D1 Receptor–Receptor Interaction and Striatal Function 24
G Protein-Dependent Activation of the PKA-Erk1/2 Pathway by the Striatal Dopamine D1/D3 Receptor Heteromer Involves Beta-Arrestin and the Tyrosine Phosphatase Shp-2 17
Generation of human induced pluripotent stem cell lines derived from three Noonan syndrome patients from a single family carrying the heterozygous PTPN11 c.188 A > G (p.Y63C) mutation 12
17-β-estradiol potentiates the neurotrophic and neuroprotective effects mediated by the dopamine D3/acetylcholine nicotinic receptor heteromer in dopaminergic neurons 11
In-vitro Approaches to Investigate the Detrimental Effect of Light on Dopaminergic Neurons 8
Totale 7.921
Categoria #
all - tutte 38.848
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.848


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.268 0 0 0 0 101 209 208 206 122 211 104 107
2020/20211.317 27 131 46 131 48 127 123 140 167 132 195 50
2021/2022861 61 130 49 24 6 15 91 42 42 103 70 228
2022/2023771 115 9 18 59 70 225 3 78 122 18 23 31
2023/2024758 56 10 69 73 34 173 27 24 137 27 20 108
2024/2025422 15 20 9 210 168 0 0 0 0 0 0 0
Totale 7.921